FONT-SIZE Plus   Neg

BioLineRx Announces Extension Of Patent For BCM By USPTO - Quick Facts

BioLineRx (BLRX) said an Issue Notification has been received from the United States Patent and Trademark Office granting 1,787 days of Patent Term Adjustment for the patent claiming the composition of BCM (BL-1040), a novel medical device for prevention of cardiac remodeling following an acute myocardial infarction.

Accordingly, the term of this patent will now extend through at least the end of April 2029, which is almost three years longer than previously reported by the company. Additional patents claiming the BL-1040 composition and its use for the treatment of ventricular remodeling and congestive heart failure due to acute myocardial infarction are granted or pending in Europe, Japan, Canada, Korea, Mexico, Israel, India, China and Australia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
General Electric Company (GE) reported that its third-quarter Industrial operating plus Verticals earnings, a non-GAAP measure, decreased 2% year-over-year to $2.87 billion. Industrial operating plus Verticals earnings per share was $0.32 compared to $0.29 prior year. On average, 15 analysts polled by... Shares of Daimler AG were losing around 3 percent in the morning trading, after the German auto giant trimmed its forecast for fiscal 2016 revenues and unit sales, while it backed adjusted EBIT view. Meanwhile, in the third quarter, the company recorded higher earnings and revenues, with increased sales volumes. German software developer SAP SE reported Friday lower profit in its third quarter due to higher stock-based compensation expense. However, revenues were higher. All regions posted improved results. Citing the strong cloud performance, the company said it is confident to deliver a strong fourth quarter, and also raised its full-year 2016 operating profit and revenue outlook.
comments powered by Disqus
Follow RTT